Our results revealed the interaction of FXN and PPARγ signaling pathway, shedding light on a pharmaceutical strategy for a positive feedback development in treating FRDA, beneficial from both diabetes and neurodegeneration. The gene discussed is FXN; the disease is diabetes mellitus.